The effects of post-surgical administration of goserelin plus anastrozole compared to goserelin alone in patients with severe endometriosis: a prospective randomized trial
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Among patients using GnRH analogues for endometriosis it has been postulated that peripheral and inflammation-induced in-situ aromatization of adrenal androgens are probably the main reasons for the high rates of failure during follow-up. We hypothesized that in cases with premenopausal severe endometriosis, use of a combination of anastrozole and goserelin to achieve almost maximal endocrine blockade of estrogen synthesis after conservative surgery may increase the pain-free interval and reduce the recurrence rates as compared to goserelin alone. METHODS: In a prospective randomized trial, we evaluated the efficacy of using either a combination of anastrozole and goserelin for 6 months or goserelin alone for 6 months after conservative surgery for severe endometriosis. The primary outcome measures were the symptom recurrence rates and the impact of treatment on endometriosis-related multidimensional score. The secondary outcome measures were the impact of allocated treatment regimens on menopausal quality of life and on lumbar spine bone mineral density (BMD). RESULTS: When we analyzed the Kaplan-Meier survival curves, we detected a statistically significant advantage of goserelin plus anastrozole as compared to goserelin only, in terms of the median time to detect symptom recurrence (>2.4 versus 1.7 months; log-rank test; P=0.0089). This statistically significant advantage occurred with a relative risk of 4.3 [95% confidence interval (CI) 1.3-9.8]. Three cases out of 40 recurred in the goserelin plus anastrozole arm (7.5%), whereas we detected recurrences in 14 cases out of 40 cases in the goserelin-only arm (35%) during the follow-up period of 24 months. Based on these data, the interpretation of Kaplan-Meier curves indicates that at the end of follow-up, 54.7 versus 10.4%, respectively, of the patients were free of recurrence. The mean of the differences in terms of Deltabaseline-24 months post-medical therapy multidimensional score were statistically significant in favour of goserelin and anastrozole (9.2 +/- 2.1 versus 6.7 +/- 2.8; paired t-test; P<0.0001; 95% CI 1.5-4.0). We observed a statistically significant difference in suppression of estradiol concentrations and a significantly greater BMD loss at the end of treatment in the goserelin and anastrozole arm as compared to goserelin-only arm. However, this did not elicit deterioration in menopausal quality of life and the observed bone loss was not significant in terms of DeltaBMD between the groups at 2 years of treatment withdrawal. CONCLUSIONS: Six months of treatment with anastrozole and goserelin as compared to goserelin alone increased the pain-free interval and decreased symptom recurrence rates in patients following surgery for severe endometriosis. Furthermore, menopausal quality of life and BMD at 2 years after medical therapy remained unaffected.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Only one study, showed a longer interval before recurrence of symptoms during the 24-month follow-up: recurrence was registered in only 3/40 (8%) of patients in the combined arm (AI + goserelin) compared to 14/40 (35%) in the goserelin-only arm ( 26 ).”
From Is intracrinology of endometriosis relevant in clinical practice? A systematic review on estrogen metabolism (2022) · cites this paper as [26]
In the citing paper
“Anastrozole (1 mg/day), administered in conjunction with goserelin for 6 months in patients with severe baseline endometriosis (rASRM score >40), showed greater improvement in pain Total Pelvic Symptom Score (TPSS) than patients using goserelin alone (ΔTPSS-P baseline -24 months PMT 5.0 vs. 3.3 p<0.0001) ( 26 ).”
From Is intracrinology of endometriosis relevant in clinical practice? A systematic review on estrogen metabolism (2022) · cites this paper as [26]
Citations
Cites
Revised American Society for Reproductive Medicine classification of endometriosis: 1996
American Society for Reproductive Medicine (1997) · Fertility and Sterility · doi:10.1016/s0015-0282(97)81391-x · Cited by 3,018
ASSESSMENT OF FRACTURE RISK AND ITS APPLICATION TO SCREENING FOR POSTMENOPAUSAL OSTEOPOROSIS
Alexeeva, L. P., Burkhardt, P., Christiansen, C., Cooper, C. C., Delmas, P. D., Johnell, O., Johnston, C. C., Kanis, J. A., Lips, P. T. A. M., Melton, L. J., et al. (1994) · Cited by 2,655
Mitwally, M. F. M., & Casper, R. F. (2001) · Fertility and Sterility · doi:10.1016/s0015-0282(00)01705-2 · Cited by 800 · cited 2×
“Aromatase inhibitors given alone are not able to completely inhibit ovarian steroidogenesis (Vignali et al., 2002), and, furthermore, may increase follicular recruitment (Mitwally and Casper, 2001) and may lead to ovarian stimulation and cyst formation.”
BackgroundInfluentialConstructing a standard climacteric scale
Greene, J. G. (1998) · Maturitas · doi:10.1016/s0378-5122(98)00025-5 · Cited by 657 · cited 2×
“The modi®ed Greene scale was used to determine the severity of vasomotor, somatic, psychological symptoms (anxiety and depression) and loss of sexual interest (Greene, 1998).”
MethodDeterminants of bone density in normal women: risk factors for future osteoporosis?
Stevenson, J. C., Lees, B., Devenport, M., Cust, M. P., & Ganger, K. F. (1989) · BMJ · doi:10.1136/bmj.298.6678.924 · Cited by 406 · cited 2×
“Furthermore, the physiological bone loss of 0.5% per year that is evident after the third decade should also be taken into account (Stevenson et al., 1989).”
BackgroundInfluentialTreatment of severe postmenopausal endometriosis with an aromatase inhibitor
Takayama, K., Zeitoun, K., Gunby, R. T., Sasano, H., Carr, B. R., & Bulun, S. E. (1998) · Fertility and Sterility · doi:10.1016/s0015-0282(98)00022-3 · Cited by 270 · cited 4×
“In the statistical analysis of the secondary outcome variables, intentionto-treat analysis (Archer and Pickar, 2002) was used; thus, it included the dropouts for whom data are not available at 24 months after postsurgical medical treatment.”
BackgroundMethodInfluentialDosage aspects of danazol therapy in endometriosis: Short-term and long-term effectiveness
Biberoglu, K. O., & Behrman, S. J. (1981) · American Journal of Obstetrics and Gynecology · doi:10.1016/0002-9378(81)90478-6 · Cited by 267 · cited 2×
“…it is recommended that postoperative adjuvant treatment should be instituted in order to minimize the risk of recurrence and to extend the pain-free period after conservative surgery in cases of severe endometriosis (American College of Obstetrics and Gynecology, 1999; Gambone et al., 2002).”
BackgroundMethodAromatase: a key molecule in the pathophysiology of endometriosis and a therapeutic target
Zeitoun, K. M., & Bulun, S. E. (1999) · Fertility and Sterility · doi:10.1016/s0015-0282(99)00393-3 · Cited by 256 · cited 2×
“In the statistical analysis of the secondary outcome variables, intentionto-treat analysis (Archer and Pickar, 2002) was used; thus, it included the dropouts for whom data are not available at 24 months after postsurgical medical treatment.”
MethodCompston, J. (1995) · Annals of the Rheumatic Diseases · doi:10.1136/ard.54.7.548 · Cited by 252
LING, F. W. (1999) · Obstetrics & Gynecology · doi:10.1097/00006250-199901000-00012 · Cited by 223 · cited 2×
“necessary in accordance with the recent literature (Hornstein et al., 1997; American College of Obstetrics and Gynecology, 1999; Ling, 1999; Vercellini et al., 1999; Winkel, 2000; Gambone et al., 2002).”
Result
Cited by
Giudice, L. C., & Kao, L. C. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17403-5 · Cited by 3,166
Endometriosis: pathogenesis and treatment
Vercellini, P., Viganò, P., Somigliana, E., & Fedele, L. (2014) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2013.255 · Cited by 1,940
Bulun, S. E. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0804690 · Cited by 1,772
Bulun, S. E., Yilmaz, B. D., Sison, C., Miyazaki, K., Bernardi, L., Liu, S., Kohlmeier, A., Yin, P., Milad, M., & Wei, J. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00242 · Cited by 844
Recurrence of endometriosis and its control
Guo, S.-W. (2009) · Human Reproduction Update · doi:10.1093/humupd/dmp007 · Cited by 719
Bulun, S. E., Lin, Z., Imir, G., Amin, S., Demura, M., Yilmaz, B., Martin, R., Utsunomiya, H., Thung, S., Gurates, B., et al. (2005) · Pharmacological Reviews · doi:10.1124/pr.57.3.6 · Cited by 531
“One randomized study (n 80) that combined an aromatase inhibitor with a GnRH agonist showed recurrence of pain in only 10% of patients in the GnRHagonist-plus-aromatase-inhibitor arm versus 55% in the GnRH-agonist-only arm within 24 months from the completion of the treatment (Soysal et al., 2004) (Fig.”
InfluentialHistory of Aromatase: Saga of an Important Biological Mediator and Therapeutic Target
Santen, R. J., Brodie, H., Simpson, E. R., Siiteri, P. K., & Brodie, A. (2009) · Endocrine Reviews · doi:10.1210/er.2008-0016 · Cited by 442
Treatment of pelvic pain associated with endometriosis: a committee opinion
(2014) · Fertility and Sterility · doi:10.1016/j.fertnstert.2014.02.012 · Cited by 397
Systematic review of endometriosis pain assessment: how to choose a scale?
Bourdel, N., Alves, J., Pickering, G., Ramilo, I., Roman, H., & Canis, M. (2015) · Human Reproduction Update · doi:10.1093/humupd/dmu046 · Cited by 372
Economic burden of endometriosis
Gao, X., Outley, J., Botteman, M., Spalding, J., Simon, J. A., & Pashos, C. L. (2006) · Fertility and Sterility · doi:10.1016/j.fertnstert.2006.06.015 · Cited by 289
Aromatase and other steroidogenic genes in endometriosis: translational aspects.
Attar, E., & Bulun, S. E. (2006) · Human Reproduction Update · doi:10.1093/humupd/dmi034 · Cited by 255
“Thus, an aromatase inhibitor was administered together with a GnRH agonist, a progestin, progesterone or a combination oral contraceptive in four phase-II trials (Amsterdam et al., 2003; Ailawadi et al., 2004; Shippen and West, 2004; Soysal et al., 2004).”
BackgroundMethodInfluentialEndometriosis and nuclear receptors
Yilmaz, B. D., & Bulun, S. E. (2019) · Human Reproduction Update · doi:10.1093/humupd/dmz005 · Cited by 243
“Inhibition of local estrogen production via aromatase inhibitors may further improve symptom relief (Takayama et al., 1998; Soysal et al., 2004).”
BackgroundHealth-related quality of life burden of women with endometriosis: a literature review
Gao, X., Yeh, Y.-C., Outley, J., Simon, J., Botteman, M., & Spalding, J. (2006) · Current Medical Research and Opinion · doi:10.1185/030079906x121084 · Cited by 206
Aromatase inhibitors: the next generation of therapeutics for endometriosis?
Attar, E., & Bulun, S. E. (2006) · Fertility and Sterility · doi:10.1016/j.fertnstert.2005.09.064 · Cited by 184
Endometriosis: Current Therapies and New Pharmacological Developments
Vercellini, P., Somigliana, E., Viganò, P., Abbiati, A., Barbara, G., & Crosignani, P. G. (2009) · Drugs · doi:10.2165/00003495-200969060-00002 · Cited by 182
“Waiting for Godot”: a commonsense approach to the medical treatment of endometriosis
Vercellini, P., Crosignani, P., Somigliana, E., Vigano, P., Frattaruolo, M. P., & Fedele, L. (2011) · Human Reproduction · doi:10.1093/humrep/deq302 · Cited by 180
“…in premenopausal women, these compounds must be used together with other drugs [e.g. GnRH agonists, danazol, oral contraceptives (OCs), progestins] that could effectively suppress gonadotrophins and reduce ovarian activity (Soysal et al., 2004; Ailawadi et al., 2005; Amsterdam et al., 2005).”
BackgroundEndometriosis: A Disease That Remains Enigmatic
Acién, P., & Velasco, I. (2013) · ISRN Obstetrics and Gynecology · doi:10.1155/2013/242149 · Cited by 178
“Therefore, aromatase inhibitors combined with GnRH analogues [75] or oral contraceptives [76] may be the next generation of endometriosis therapy.”
BackgroundEndometriosis and Ovarian Cancer: A Review of Clinical, Pathologic, and Molecular Aspects
Wei, J.-J., William, J., & Bulun, S. (2011) · International Journal of Gynecological Pathology · doi:10.1097/pgp.0b013e31821f4b85 · Cited by 174
“Peripheral and/or local aromatase activity in endometriosis may be particularly important because a combination of a GnRH agonist and an aromatase inhibitor is significantly superior to only GnRH agonist for providing long-lasting pain relief in patients with severe endometriosis (106).”
BackgroundThe Role of Endometrium in Endometriosis
Ulukus, M., Cakmak, H., & Arici, A. (2006) · Journal of the Society for Gynecologic Investigation · doi:10.1016/j.jsgi.2006.07.005 · Cited by 170
Medical and surgical management of adenomyosis
Farquhar, C., & Brosens, I. (2006) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2006.01.012 · Cited by 170
Bellet, M., Gray, K. P., Francis, P. A., Láng, I., Ciruelos, E., Lluch, A., Climent, M. A., Catalán, G., Avella, A., Bohn, U., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.61.2259 · Cited by 161
“Baseline hormone levels E2, pg/mL, median (IQR) 41 (5-110) 65 (27-115) 50 (6-110) .”
InfluentialPharmacologic therapies in endometriosis: a systematic review
Soares, S. R., Martínez‐Varea, A., Hidalgo‐Mora, J. J., & Pellicer, A. (2012) · Fertility and Sterility · doi:10.1016/j.fertnstert.2012.07.1120 · Cited by 165
Estrogen metabolism and action in endometriosis
Rižner, T. L. (2009) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2009.03.022 · Cited by 153
Current and emerging treatment options for endometriosis
Ferrero, S., Evangelisti, G., & Barra, F. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1494154 · Cited by 152
“Furthermore, an RCT showed that, after conservative surgery for endometriosis, the administration of AI combined with GnRH-a for 6 months is more efficacious than GnRH-a monotherapy in increasing the pain-free interval and in decreasing the recurrence rates of pain [60].”
BackgroundMedical treatment for rectovaginal endometriosis: what is the evidence?
Vercellini, P., Crosignani, P. G., Somigliana, E., Berlanda, N., Barbara, G., & Fedele, L. (2009) · Human Reproduction · doi:10.1093/humrep/dep231 · Cited by 144
Guo, S.-W. (2007) · Gynecologic and Obstetric Investigation · doi:10.1159/000096047 · Cited by 144
“Therefore, existing and investigational medications for treating endometriosis all share the commonality of suppression of NF-B activation (fig. 8 ). One possible exception may be the aromatase inhibitors, which have been shown to be effective in treating postmenopausal endometriosis [ , , , , ,”
BackgroundTaniguchi, F. (2011) · Frontiers in Bioscience · doi:10.2741/e277 · Cited by 141
“Aromatase inhibitors have been successfully used for the treatment of endometriosis (115, 116).”
MethodAromatase inhibitors for the treatment of endometriosis
Pavone, M. E., & Bulun, S. E. (2012) · Fertility and Sterility · doi:10.1016/j.fertnstert.2012.08.053 · Cited by 138
“Both treatment protocols proved to be statistically effective in reducing the TPSS during the study period (43).”
BackgroundInfluentialEndometriosis: current and future medical therapies
Vercellini, P., Somigliana, E., Viganò, P., Abbiati, A., Daguati, R., & Crosignani, P. G. (2007) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2007.10.001 · Cited by 150
Recchia, F., Saggio, G., Amiconi, G., Blasio, A. D., Cesta, A., Candeloro, G., & Rea, S. (2005) · Cancer · doi:10.1002/cncr.21646 · Cited by 133
“In a different disease setting, endometriosis, in which estrogen suppression is fundamental for disease control, a statistically significant advantage has been demonstrated with the Gn-RH analogue plus anastrazole inhibitor compared with the Gn-RH analogue alone.(29) In addition, it has been shown recently that the fu…”
MethodFerrero, S., Camerini, G., Seracchioli, R., Ragni, N., Venturini, P. L., & Remorgida, V. (2009) · Human Reproduction · doi:10.1093/humrep/dep302 · Cited by 134
“, 2004; Shippen and West, 2004) or as a post-operative prevention of recurrence (Soysal et al., 2004).”
BackgroundCurrent and Emerging Therapeutics for the Management of Endometriosis
Ferrero, S., Barra, F., & Maggiore, U. L. R. (2018) · Drugs · doi:10.1007/s40265-018-0928-0 · Cited by 155
Dysmenorrhea in Adolescents: Diagnosis and Treatment
French, L. (2008) · Pediatric Drugs · doi:10.2165/00148581-200810010-00001 · Cited by 167
Angiogenesis and antiangiogenic therapy in endometriosis
Becker, C. M., & D’Amato, R. J. (2007) · Microvascular Research · doi:10.1016/j.mvr.2007.04.008 · Cited by 131
Systematic review of the effects of aromatase inhibitors on pain associated with endometriosis
Patwardhan, S., Nawathe, A., Yates, D., Harrison, G., & Khan, K. (2008) · BJOG: An International Journal of Obstetrics & Gynaecology · doi:10.1111/j.1471-0528.2008.01740.x · Cited by 116
Use of aromatase inhibitors to treat endometriosis-related pain symptoms: a systematic review
Ferrero, S., Gillott, D. J., Venturini, P. L., & Remorgida, V. (2011) · Reproductive Biology and Endocrinology · doi:10.1186/1477-7827-9-89 · Cited by 109
“Three studies investigated the use of AIs as postoperative therapy in preventing the recurrence of pain after surgical treatment of endometriosis [39,45,46]; seven studies examined the effect of AIs in improving endometriosis-related pain symptoms.”
BackgroundMethodInfluentialAromatase expression in endometriotic tissues and cell cultures of patients with endometriosis
Velasco, I. (2006) · Molecular Human Reproduction · doi:10.1093/molehr/gal041 · Cited by 108
“In recent clinical trials, aromatase inhibitors combined with GnRH analogues ( Soysal et al., 2004 ) or oral contraceptives (Amsterdam et al., 2005) seem to decrease endometriosis symptoms, and no significant side effects were noted.”
BackgroundAn update on the pharmacological management of endometriosis
Streuli, I., de Ziegler, D., Santulli, P., Marcellin, L., Borghese, B., Batteux, F., & Chapron, C. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2013.767334 · Cited by 104
“A RCT compared a post-operative 6-month treatment of anastrazole associated with goserelin to goserelin alone and found an increase in the disease-free interval in women with the combination therapy [84].”
MethodTakemura, Y., Osuga, Y., Yoshino, O., Hasegawa, A., Hirata, T., Hirota, Y., Nose, E., Morimoto, C., Harada, M., Koga, K., et al. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-2486 · Cited by 117
Variation in outcome reporting in endometriosis trials: a systematic review
Hirsch, M., Duffy, J. M., Kusznir, J. O., Davis, C., Plana, N., Khan, K. S., Duffy, J. M. N., Farquhar, C. M., Hirsch, M., Johnson, N., et al. (2016) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2015.12.039 · Cited by 108
“There is wide variation in outcome and outcome measures used in RCTs evaluating surgical intervention and their medical adjuncts for endometriosis.”
InfluentialHormonal therapy for endometriosis: from molecular research to bedside
Tosti, C., Biscione, A., Morgante, G., Bifulco, G., Luisi, S., & Petraglia, F. (2017) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2016.05.032 · Cited by 96
“A significantly longer time to symptom recurrence was observed in women who received the combined regimen, and no differences in quality of life or bone mass were found between the groups [25].”
Hefler, L., Grimm, C., van Trotsenburg, M., & Nagele, F. (2005) · Fertility and Sterility · doi:10.1016/j.fertnstert.2005.04.059 · Cited by 94
Endometriosis after menopause: physiopathology and management of an uncommon condition
Streuli, I., Gaitzsch, H., Jm, W., & Petignat, P. (2017) · Climacteric · doi:10.1080/13697137.2017.1284781 · Cited by 97
Endometriosis and Chronic Pelvic Pain: Unraveling the Mystery Behind this Complex Condition
Bloski, T. G., & Pierson, R. A. (2008) · Nursing for Women s Health · doi:10.1111/j.1751-486x.2008.00362.x · Cited by 107
The Physiology and Pathology of the Female Reproductive Axis
Bulun, S. E., Adashi, E. Y., & Bulun, S. E. (2007) · Time to knit · doi:10.1016/b978-1-4160-2911-3.50018-2 · Cited by 92
Safety of medical treatments for endometriosis
Berlanda, N., Somigliana, E., Viganò, P., & Vercellini, P. (2016) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2016.1121991 · Cited by 78
Ferrero, S., Venturini, P. L., Gillott, D. J., & Remorgida, V. (2011) · Reproductive Biology and Endocrinology · doi:10.1186/1477-7827-9-88 · Cited by 75
“Previous studies in women with endometriosis combined aromatase inhibitors (letrozole or anastrozole) with combined oral contraceptive pills [7], norethisterone acetate [8-12] or gonadotropin-releasing hormone analogues [13,14].”
BackgroundResultHarada, T. (2007) · Frontiers in Bioscience · doi:10.2741/2302 · Cited by 77
Emerging drugs for endometriosis
Fedele, L., & Berlanda, N. (2004) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.9.1.167 · Cited by 73
Treatment strategies for endometriosis
Rodgers, A. K., & Falcone, T. (2008) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.9.2.243 · Cited by 73
“One study found no change in bone density at 6 months after use of an aromatase inhibitor with an oral contraceptive in premenopausal women, and another found a decrease in bone density with the use of aromatase inhibitor with a GnRH agonist after 6 months of use in premenopausal women [71,79] .”
BackgroundEbert, A. D., Bartley, J., & David, M. (2005) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2005.04.017 · Cited by 80
Letrozole and norethisterone acetate in rectovaginal endometriosis
Remorgida, V., Abbamonte, L. H., Ragni, N., Fulcheri, E., & Ferrero, S. (2007) · Fertility and Sterility · doi:10.1016/j.fertnstert.2006.12.027 · Cited by 72
A comprehensive review of hormonal and biological therapies for endometriosis: latest developments
Barra, F., Grandi, G., Tantari, M., Scala, C., Facchinetti, F., & Ferrero, S. (2019) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2019.1581761 · Cited by 69
“Another recent pre-clinical study showed that bevacizumab was as efficacious as GnRH-agonists in inducting the apoptosis of ectopic endometrial cells, thus, causing the regression of endometriotic lesions [84,131].”
BackgroundRecurrent endometriosis: a battle against an unknown enemy
Ceccaroni, M., Bounous, V. E., Clarizia, R., Mautone, D., & Mabrouk, M. (2019) · The European Journal of Contraception & Reproductive Health Care · doi:10.1080/13625187.2019.1662391 · Cited by 67
“The recurrence rate is, in fact, extrapolated from a variety of studies with different aims: some studies compare different surgical procedures [9,27,38,41,49], while others compare different postoperative therapies [10,23,45], evaluate whether no therapy is better than postoperative therapy [17,21,26,28,43,46,52], or…”
BackgroundResultFatemi, H. M., Al-Turki, H., Papanikolaou, E. G., Kosmas, L., Sutter, P. D., & Devroey, P. (2005) · Reproductive BioMedicine Online · doi:10.1016/s1472-6483(10)61140-6 · Cited by 70
Endometriosis: New Genetic Approaches and Therapy
Barlow, D. H., & Kennedy, S. (2005) · Annual Review of Medicine · doi:10.1146/annurev.med.55.091902.103805 · Cited by 64
“Anastrazole plus GnRHa increased the pain-free interval and decreased symptom recurrence rates following surgery for severe endometriosis (56).”
BackgroundPharmacological Treatment of Endometriosis: Experience with Aromatase Inhibitors
Ferrero, S., Venturini, P. L., Ragni, N., Camerini, G. B., & Remorgida, V. (2009) · Drugs · doi:10.2165/00003495-200969080-00001 · Cited by 70
Aromatase inhibitors in post-menopausal endometriosis
Polyzos, N. P., Fatemi, H. M., Zavos, A., Grimbizis, G., Kyrou, D., Velasco, J.-G., Devroey, P., Tarlatzis, B., & Papanikolaou, E. G. (2011) · Reproductive Biology and Endocrinology · doi:10.1186/1477-7827-9-90 · Cited by 63
“Available evidence regarding the use of AIs for the treatment of postmenopausal endometriosis Although a prospective randomized trial showed that AIs in combination with GnRH analogues increased the pain-free interval and decreased symptoms recurrence rates following surgery in premenopausal patients with severe endom…”
BackgroundNew trends for the medical treatment of endometriosis
Rocha, A. L. L., Reis, F. M., & Petraglia, F. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2012.683783 · Cited by 60
“In a randomized trial, the combination of AI and GnRH analog was more effective to reduce pain than GnRH analog alone [40].”
BackgroundCurrent pharmacotherapy for endometriosis
Ferrero, S., Remorgida, V., & Venturini, P. L. (2010) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656561003685880 · Cited by 58
“[84] 40 Anastrozole (oral, 1 mg/day) Goreselin (3.”
BackgroundComparison of the effects of raloxifene and anastrozole on experimental endometriosis
Altintas, D., Kokcu, A., Kandemir, B., Tosun, M., & Cetinkaya, M. B. (2010) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2010.02.004 · Cited by 57
“004 suppression [1,2] but the drugs combined with it have important side effects that cannot be underestimated.”
BackgroundInvestigational drugs for the treatment of endometriosis, an update on recent developments
Barra, F., Scala, C., Mais, V., Guerriero, S., & Ferrero, S. (2018) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2018.1471135 · Cited by 57
“Two randomized controlled trials demonstrated that the post-surgical administration of AIs as monotherapy or in combination with GnRH-as decreased more the risk of recurrence of endometriosis when compared with single GnRH-as or danazol [37,38].”
BackgroundAromatase inhibitors in the treatment of endometriosis
Słopień, R., & Męczekalski, B. (2016) · Menopause Review/Przegląd Menopauzalny · doi:10.5114/pm.2016.58773 · Cited by 74
“Letrozole administered in combination with aGnRH for six months after surgery was superior to aGnRH monotherapy in patients with endometriosis [14, 15].”
BackgroundPharmacological Management of Chronic Pelvic Pain in Women
Carey, E. T., Till, S. R., & As‐Sanie, S. (2017) · Drugs · doi:10.1007/s40265-016-0687-8 · Cited by 67
Future Perspectives in the Medical Treatment of Endometriosis
Ferrero, S., Abbamonte, L. H., Anserini, P., Remorgida, V., & Ragni, N. (2005) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000189153.87365.dc · Cited by 57
“Recently, in a prospective, randomized trial, Soysal et al (13) demonstrated that 6 months of treatment with anastrozole (1 mg/day) and goserelin as compared with goserelin alone increased the pain-free interval and decreased symptom recurrence rates in patients after surgery for severe endometriosis.”
BackgroundThe role of pharmacotherapy in the treatment of endometriosis across the lifespan
Schwartz, K. M., Llarena, N. C., Rehmer, J. M., Richards, E. G., & Falcone, T. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1738386 · Cited by 60
Endometriosis: The way forward
Hompes, P. G. A., & Mijatovic, V. (2007) · Gynecological Endocrinology · doi:10.1080/09513590601010474 · Cited by 55
“Apart from some case reports the current clinical evidence is based on one randomized trial [54] and two observational studies [55,56].”
BackgroundThe emerging use of aromatase inhibitors for endometriosis treatment
Nothnick, W. B. (2011) · Reproductive Biology and Endocrinology · doi:10.1186/1477-7827-9-87 · Cited by 55
“N = 40 goserelin + anastrozole) Decreased symptom recurrence rate Increased pain-free interval [21] Soysal et al.”
BackgroundAromatase inhibition for refractory endometriosis-related chronic pelvic pain
Abushahin, F., Goldman, K. N., Barbieri, E., Milad, M., Rademaker, A., & Bulun, S. E. (2011) · Fertility and Sterility · doi:10.1016/j.fertnstert.2011.07.1136 · Cited by 53
Aromatase inhibitors in recurrent ovarian endometriomas: report of five cases with literature review
Seal, S. L., Kamilya, G., Mukherji, J., De, A., Ghosh, D., & Majhi, A. K. (2010) · Fertility and Sterility · doi:10.1016/j.fertnstert.2010.05.021 · Cited by 52
Potential role of aromatase inhibitors in the treatment of endometriosis
Abu Hashim, H. (2014) · International Journal of Women's Health · doi:10.2147/ijwh.s34684 · Cited by 46
“21 Analysis of the case series/reports showed that AIs combined with progestins or the oral contraceptive pill or GnRHas reduced mean pain scores and lesion size and improved quality of life.”
InfluentialOn-label and off-label drug use in the treatment of endometriosis
Quaas, A. M., Weedin, E. A., & Hansen, K. R. (2015) · Fertility and Sterility · doi:10.1016/j.fertnstert.2015.01.006 · Cited by 45
Piccinato, C. A., Neme, R. M., Torres, N., Sanches, L. R., Derogis, P. B. M. C., Brudniewski, H. F., Rosa e Silva, J. C., & Ferriani, R. A. (2016) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2015.12.025 · Cited by 45
“The significance of estrogen biosynthesis/metabolism in endometriosis has been supported by substantial clinical and epidemiological evidence, such as the high incidence of endometriosis in women during their reproductive years and the apparent efficacy of antiestrogenic therapy for symptom relief and reduced recurren…”
Riggs, M., Bennetts, M., van der Graaf, P., & Martin, S. (2012) · CPT: Pharmacometrics & Systems Pharmacology · doi:10.1038/psp.2012.10 · Cited by 43
Prise en charge d'une endométriose douloureuse
Roman, H. (2007) · Journal de gynécologie, obstétrique et biologie de la reproduction. Supplément/Journal de gynécologie obstétrique et biologie de la reproduction · doi:10.1016/j.jgyn.2006.12.008 · Cited by 52
Tolerability considerations for gonadotropin-releasing hormone analogues for endometriosis
Corte, L. D., Barra, F., Mercorio, A., Evangelisti, G., Rapisarda, A. M. C., Ferrero, S., Bifulco, G., & Giampaolino, P. (2020) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2020.1789591 · Cited by 49
Verma, A., & Konje, J. C. (2009) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2008.12.002 · Cited by 47
Løssl, K., Loft, A. G., Freiesleben, N. L. C., Bangsbøll, S., Andersen, C. Y., Pedersen, A. T., Hartwell, D., & Andersen, A. N. (2009) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2009.02.001 · Cited by 43
Physiology and Pathology of the Female Reproductive Axis
Bulun, S. E. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4377-0324-5.00017-1 · Cited by 48
Aspectos atuais do diagnóstico e tratamento da endometriose
Nácul, A. P., & Spritzer, P. M. (2010) · Revista Brasileira Ginecologia e Obstetrícia · doi:10.1590/s0100-72032010000600008 · Cited by 155
Gonadotropin-releasing hormone analogues for endometriosis
Veth, V. B., van de Kar, M. M., Duffy, J. M., van Wely, M., Mijatovic, V., & Maas, J. W. (2023) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd014788.pub2 · Cited by 39
Evolving Spectrum: The Pathogenesis of Endometriosis
Jensen, J. R., & Coddington, C. C. (2010) · Clinical Obstetrics & Gynecology · doi:10.1097/grf.0b013e3181db7b84 · Cited by 52
“Clinically, aromatase inhibitors may be an important adjunct for treating endometriosis—pain relief is significantly improved with the combination of GnRH agonist plus aromatase inhibitor over GnRH agonist alone in women with severe endometriosis.(65) Endometriosis is a complex disease with several key steps yet to be…”
BackgroundUse of aromatase inhibitors in practice of gynecology
Usluogullari, B., Duvan, C. Z., & Usluogullari, C. A. (2015) · Journal of Ovarian Research · doi:10.1186/s13048-015-0131-9 · Cited by 39
“At the studies suggested that effective dose of aromatase inhibitors for the management of pain associated with endometriosis are usually 1 mg daily anastrazole and 2,5 mg daily letrozole [17,18].”
BackgroundExtrapelvic Endometriosis Complicated with Colonic Obstruction
Lin, Y., Kuo, L., Chuang, A., Cheng, T.-I., & Hung, C.-F. (2006) · Journal of the Chinese Medical Association · doi:10.1016/s1726-4901(09)70111-x · Cited by 40
A peek into the drug development scenario of endometriosis – A systematic review
Goenka, L., George, M., & Sen, M. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.03.092 · Cited by 37
Advances in pharmacotherapy for treating endometriosis
Tafi, E., Leone Roberti Maggiore, U., Alessandri, F., Bogliolo, S., Gardella, B., Vellone, V. G., Grillo, F., Mastracci, L., & Ferrero, S. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1085510 · Cited by 36
“AIs could play a role in preventing the recurrence of endometriosis after surgical treatments; three RTCs investigating this issue reported conflicting results [74,78,79].”
ResultEmerging therapy for endometriosis
Lindsay, S. F., Luciano, D. E., & Luciano, A. A. (2015) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2015.1051966 · Cited by 45
“Both groups otherwise had similar symptoms of hypoestrogenemia [44].”
BackgroundInfluentialGarzon, S., Laganà, A. S., Barra, F., Casarin, J., Cromi, A., Raffaelli, R., Uccella, S., Franchi, M. P., Ghezzi, F., & Ferrero, S. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1842356 · Cited by 48
The American College of Obstetricians and Gynecologists: WOMEN’S HEALTH CARE PHYSICIANS
(2018) · Obstetrics and Gynecology · doi:10.1097/aog.0000000000002640 · Cited by 44
Othman, E.-E. R., Salama, S., Ismail, N., & Al-Hendy, A. A. (2007) · Fertility and Sterility · doi:10.1016/j.fertnstert.2006.11.046 · Cited by 35
Advances in targeting estrogen synthesis and receptors in patients with endometriosis
Clemenza, S., Vannuccini, S., Ruotolo, A., Capezzuoli, T., & Petraglia, F. (2022) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2022.2152325 · Cited by 38
Bohrer, J. C., Chen, C. C. G., & Falcone, T. (2008) · Fertility and Sterility · doi:10.1016/j.fertnstert.2008.03.040 · Cited by 32
Endometriosis Pain Management: a Review
Carlyle, D., Khader, T., Lam, D., Vadivelu, N., Shiwlochan, D., & Cho, Y. (2020) · Current Pain and Headache Reports · doi:10.1007/s11916-020-00884-6 · Cited by 62
Schultze-Mosgau, M.-H., Waellnitz, K., Nave, R., Klein, S., Kraetzschmar, J., Rautenberg, T., Schmitz, H., & Rohde, B. (2016) · Human Reproduction · doi:10.1093/humrep/dew145 · Cited by 31
New drugs in development for the treatment of endometriosis
Fedele, L., Somigliana, E., Frontino, G., Benaglia, L., & Vigano, P. (2008) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.17.8.1187 · Cited by 30
“Bone loss at the spine resulted significantly higher in women receiving the regimen with anastrozole at 6 months but this difference was not detected at 24 months [48] .”
BackgroundMethodCantor, A., Tannus, S., Son, W., Tan, S. L., & Dahan, M. H. (2018) · Reproductive BioMedicine Online · doi:10.1016/j.rbmo.2018.12.028 · Cited by 34
Peitsidis, P., Tsikouras, P. N., Laganà, A. S., Laios, A., Gkegkes, I. D., & Iavazzo, C. R. (2023) · Drug Design Development and Therapy · doi:10.2147/dddt.s315726 · Cited by 34
“0001) compared with GnRH analogs alone.(41) Lesion size was assessed according to ASRM (American Society of Reproductive Medicine) score of(42) in a nonrandomized study the authors reported a reduction of lesion size after combined treatment with letrozole and norethindrone.”
MethodAromatase inhibitor treatment limits progression of peritoneal endometriosis in baboons
Langoi, D., Pavone, M. E., Gürateş, B., Chai, D. C., Fazleabas, A. T., & Bulun, S. E. (2012) · Fertility and Sterility · doi:10.1016/j.fertnstert.2012.11.021 · Cited by 32
Advances in the medical management of endometriosis
Panay, N. (2008) · BJOG An International Journal of Obstetrics & Gynaecology · doi:10.1111/j.1471-0528.2008.01739.x · Cited by 29
Conservative surgical management of endometriosis in women with pelvic pain
Frishman, G. N., & Salak, J. R. (2006) · Journal of Minimally Invasive Gynecology · doi:10.1016/j.jmig.2006.06.023 · Cited by 30
Metadata
- Authors
- Soysal, S.
- Affiliations
- Pamukkale Üniversitesi Hastaneleri (TR)
- Corresponding author
- Soysal, S.
- Venue
- Human Reproduction
- Publisher
- Oxford University Press (OUP)
- Published
- 2004-01-01
- Volume
- 19
- Issue
- 1
- Pages
- 160-167
- ISSN
- 0268-1161 (ISSN-L)
- 1460-2350
- OpenAlex
- W2149342667
- Cited by
- 227
- References
- 24
- Citations by year
- 2026: 4 · 2025: 5 · 2024: 12 · 2023: 6 · 2022: 5 · 2021: 8 · 2020: 5 · 2019: 8 · 2018: 9 · 2017: 8 · 2016: 10 · 2015: 10 · 2014: 7 · 2013: 10 · 2012: 12
- FWCI
- 8.88
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- other-oa
- Locations
- Human Reproduction (publishedVersion)
- PubMed (publishedVersion)
- Hacettepe University Institutional Repository (hacettepe.edu.tr) (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Endometriosis Research and Treatment
- Health Sciences › Medicine › Obstetrics and Gynecology › Endometrial and Cervical Cancer Treatments
- Health Sciences › Medicine › Obstetrics and Gynecology › Ectopic Pregnancy Diagnosis and Management
- Keywords
- endometriosis, goserelin, anastrozole, GnRH analogues, aromatase inhibitors, combination endocrine therapy, conservative surgery, symptom recurrence, bone mineral density, lumbar spine, estrogen synthesis, premenopausal women
- MeSH terms
- Anastrozole, Adult, Drug Administration Schedule, Drug Therapy, Combination, Endometriosis, Enzyme Inhibitors, Estradiol, Female, Humans, Menopause, Nitriles, Palliative Care, Postoperative Care, Quality of Life, Severity of Illness Index, Triazoles, Bone Density, Survival Analysis, Treatment Outcome, Goserelin, Patient Selection, Aromatase Inhibitors, Secondary Prevention
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.